Oncology Central

Promising Phase 1b clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer

A Phase 1b clinical trial investigating tucatinib combined with ado-trastuzumab emtansine (T-DM1) in advanced ERBB2/HER2-positive metastatic breast cancer has yielded encouraging results.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.